Yutaka Matsuda
Director Exelixis
Seminars
Tuesday 4th November 2025
Unveiling Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC
12:00 pm
- Introducing XB371 design as a novel belotecan ADC, created with the SMARTag ADC design platform
- Laying out a demonstration of in vitro bystander and ICD activity
- Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models
